Nomura has reiterated its Buy rating on Cipla, setting a target price of ₹1,780 per share, implying a 25% upside from the current market price of ₹1,427.00.
The company’s Q3 earnings came in ahead of estimates, reflecting strong operational performance. However, delays in key US drug launches have impacted FY26 estimates, though FY27 projections remain unchanged.
Despite short-term challenges, Nomura remains bullish on Cipla’s long-term growth prospects, citing its robust domestic business and strong pipeline for the US market.
Disclaimer: The views and investment recommendations expressed in this article are those of the brokerage firm and do not constitute financial advice. Readers are advised to consult with a certified financial advisor before making any investment decisions. Business Upturn is not responsible for any financial losses resulting from investment actions based on this article.
